Sector News

Merck offers EU concessions over $17 bln Sigma-Aldrich buy

May 28, 2015
Life sciences
(Reuters) – German drugmaker Merck has offered concessions in a bid to convince European Union antitrust regulators to clear its proposed $17 billion acquisition of U.S. peer Sigma-Aldrich Corp.
 
Earlier this month, Merck said the European Commission expressed concerns “of a limited nature” over its biggest ever takeover. It submitted concessions on May 22, according to a filing on the EU executive’s website. No details were provided.
 
The EU competition watchdog will now decide by June 15 instead of June 1 whether to approve the takeover.
 
Companies typically offer to sell overlapping assets or provide rivals access to technologies or patents to allay regulatory worries that the merged entity may have an excessive market share. (Reporting by Foo Yun Chee. Editing by Jane Merriman)

comments closed

Related News

October 23, 2021

Novo Nordisk teams with CVS Health on obesity support program ahead of Wegovy DTC launch

Life sciences

As Novo Nordisk gears up to disrupt the obesity market with its newly approved weight-loss drug Wegovy, it is teaming with retail pharmacy giant CVS Health on a new education and nutrition coaching program for people taking anti-obesity meds.

October 23, 2021

GSK-backed Atreca inks license with Gates Medical Research Institute for malaria monoclonal antibody

Life sciences

The terms of the deal were undisclosed, but Atreca received $6 million from the Gates Foundation in 2012 to discover potential treatments for malaria, tuberculosis and HIV. The foundation has also given grant money to other biopharmas exploring malaria treatments, including Exscientia, which secured $4.2 million last year for such work.

October 23, 2021

A record number of biotechs are going public. Here’s how they’re performing.

Life sciences

At the start of the last decade, the IPO markets weren’t receptive to biotech companies. But by 2013, public investment was pouring into the industry, drawn by scientific advances and boosted by the newfound interest of a broader range of investors. Ever since, biotechs and their backers have ridden a multi-year boom. Keep track of them as they happen with this database.

Send this to a friend